Skip to main content
CC logo

CC · Chemours Co · Documents

Track CC — free
$11.92 -0.17 (-1.41%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.82B
Shares
150.53M
Volume · Nov 19 337.46K Avg daily vol (3M) 2.1M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report Ended Dec 31, 2025 Revenue $5.81B up 0.4% 10-K filed Feb 24, 2026 Quarterly report FY2026 Q3 Revenue $1.54B up 3.0% 10-Q filed Nov 5, 2026 Latest results Third-quarter sales rise as adjusted EBITDA reaches $200 million 8-K filed Nov 2, 2026 Earnings call Q3 2026 earnings call Held Nov 3, 2026
2026
Nov 18
Current report 8-K Events of Nov 16
Chemours General Counsel Kristine Wellman to retire; Amy Rocklin named successor

Kristine Wellman, Senior Vice President, General Counsel & Corporate Secretary, plans to retire, and Amy M. Rocklin will succeed her effective January 4, 2027. Wellman will then serve as Senior Vice President, Senior Counsel until May 7, 2027.

Director or officer change, or executive pay
3 source passages
Kristine M. Wellman, Senior Vice President, General Counsel & Corporate Secretary, plans to retire from her position, and the Company has selected Amy M. Rocklin to succeed Ms. Wellman effective January 4, 2027 (the “Transition Date”) Following the Transition Date, Ms. Wellman will serve as Senior Vice President, Senior Counsel until May 7, 2027. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Third-quarter sales rose 3% to $1.5 billion

Chemours reported third-quarter net sales of $1.5 billion, up 3%. Titanium Technologies Adjusted EBITDA rose to $85 million and margin to 13%, while Thermal & Specialized Solutions Adjusted EBITDA fell to $136 million and margin to 27%.

Revenue $1.54B ▲ 3.0% Net income $196M ▲ 326.1% Diluted EPS $1.29 ▲ 316.1%
Read from the MD&A section
3 source passages
Our net sales increased by $45 million (or 3%) to $1.5 billion for the three months ended September 30, 2026, compared with net sales of $1.5 billion for the same period in 2025. For the three months ended September 30, 2026 segment Adjusted EBITDA increased by $60 million (or over 100%) to $85 million and Adjusted EBITDA margin increased by approximately 900 basis points to 13%, compared with segment Adjusted EBITDA of $25 million and Adjusted EBITDA margin of 4% for the same period in 2025. For the three months ended September 30, 2026, segment Adjusted EBITDA decreased by $58 million (or 30%) to $136 million and Adjusted EBITDA margin decreased by approximately 800 basis points to 27%, compared with segment Adjusted EBITDA of $194 million and Adjusted EBITDA margin of 35% for the same period in 2025. Open the document at this passage
Nov 3
Annual report 10-K/A Ended Dec 31
Disclosure controls were ineffective due to omitted internal-control report

Chemours’ disclosure controls were not effective as of December 31, 2025 because an administrative error omitted its internal-control report. The issue persisted until the third quarter of 2026, when additional reviews were implemented; consolidated financial statements were unaffected.

Read from the first part of this long document
3 source passages
Amendment No. 1 amends the Annual Report on Form 10-K of The Chemours Company (the “Company” or “Chemours”) for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission (the “SEC”) on February 24, 2026 (the “Original Filing”). The ineffectiveness of the Company’s disclosure controls and procedures existed from December 31, 2025 until the third quarter of 2026. In addition to the Company’s existing disclosure controls and procedures, during the third quarter of 2026, management implemented additional review procedures to provide reasonable assurance over the completeness of the non-financial statement disclosure requirements of the applicable SEC form. This Amendment No. 1 does not affect the Company’s consolidated financial statements included in the Original Filing. Open the document at this passage
Nov 3
Earnings call
Adjusted EBITDA $200 million; outlook $775 million to $800 million

Chemours reported adjusted EBITDA of $200 million, at the high end of guidance. It expects 2026 adjusted EBITDA of $775 million to $800 million, free cash flow conversion of 15% to 20%, and net leverage below 4.2 times adjusted EBIT.

5 source passages
Adjusted EBITDA was $200 million at the high end of our guidance range, with all businesses contributing above expectations. we now expect net sales to grow around 2% compared with 2025 and adjusted EBITDA to now be between $775 million and $800 million. we now anticipate free cash flow conversion to be between 15% to 20%, which reflects capital expenditures between $220 million and $230 million. Our net leverage ratio is now expected to be below 4.2 times adjusted EBIT at the end of 2026. We remain focused on controlling what we can control and are confident in the cost measures we have taken and the improvements we are driving across our operational circuit through the Chemours business system to strengthen our resilience and execution. Open the document at this passage
Nov 2
Current report 8-K
Third-quarter sales rise as adjusted EBITDA reaches $200 million

Chemours reported third-quarter Net Sales of $1.5 billion and Adjusted EBITDA of $200 million, while net income reached $196 million. For 2026, Net Sales are expected to grow approximately 2%, with Adjusted EBITDA of $775 million to $800 million.

Financial results Read from the first part of this long document
5 source passages
The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions (“TSS”), Titanium Technologies (“TT”), and Advanced Performance Materials (“APM”), today announced its financial results for the third quarter 2026. Net Sales of $1.5 billion, up slightly from the prior-year quarter, reflecting an approximately 10% year-over-year pricing increase in TT and 26% year-over-year growth in APM Performance Solutions. Adjusted EBITDA for the third quarter of 2026 was $200 million, compared with $189 million in the prior-year quarter. Net Income attributable to Chemours of $196 million, or $1.29 per diluted share, compared with Net Income attributable to Chemours of $46 million, or $0.31 per diluted share, in the corresponding prior-year quarter. The Company expects 2026 Net Sales to grow approximately 2% over 2025, with Adjusted EBITDA between $775 million and $800 million. Open the document at this passage
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.59B ▼ 1.5% Net loss $274M Diluted EPS -$1.81
May 5
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $1.38B ▲ 1.0% Net loss $29M Diluted EPS -$0.19
Mar 10
Proxy statement DEF 14A Meeting Apr 24, 2026
Proxy statement AI summary on its way
Feb 26
Current report 8-K
Other events AI summary on its way
2025
Showing 1–50 of 199 documents
Key facts CIK 1627223 CUSIP 163851108 13F (30d) 463 filings 395 filers Visit website Investor relations